Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.59 |
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.59 |
| ▸ | OSBP | P22059 | 1/20 | 0.59 |
| ▸ | RORC | P51449 | 1/20 | 0.59 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.59 |
| ▸ | POLA1 | P09884 | 1/20 | 0.56 |
| ▸ | GRIN1 | Q05586 | 13/20 | 0.56 |
| ▸ | GRIN2B | Q13224 | 13/20 | 0.56 |
| ▸ | GRIN2A | Q12879 | 11/20 | 0.56 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.52 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.52 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22658123 | 1.00 | USP2 (0.59) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL8205164 | 1.00 | USP2 (0.59) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL1050027 | 1.00 | USP2 (0.59) | USP2CYP46A1LMNAABCB1OSBP | |
| Hydrochloric Acid SCHEMBL11907786 | 0.99 | USP2 (0.58) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL14056349 | 0.92 | USP2 (0.57) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL19691912 | 0.91 | USP2 (0.60) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL998341 | 0.91 | USP2 (0.60) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL19692309 | 0.91 | USP2 (0.60) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL3359948 | 0.91 | USP2 (0.60) | USP2CYP46A1LMNAABCB1OSBP | |
| SCHEMBL2440566 | 0.90 | OSBP (0.58) | USP2CYP46A1LMNAABCB1OSBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2833869-B1 | METHOD OF PREPARING COMPOSITION FOR DELIVERING AN ANIONIC DRUG | SAMYANG BIOPHARMACEUTICALS (KR) | 2020-10-28 | — | — | EP | claimed |
| US-9486510-B2 | Method to enhance an immune response of nucleic acid vaccination | LIPOXEN TECHNOLOGIES LIMITED (GB) | 2016-11-08 | — | — | US | claimed |
| US-8828405-B2 | Method to enhance an immune response of nucleic acid vaccination | LIPOXEN TECHNOLOGIES LIMITED (GB) | 2014-09-09 | — | — | US | claimed |
| US-20120121690-A1 | METHOD TO ENHANCE AN IMMUNE RESPONSE OF NUCLEIC ACID VACCINATION | LIPOXEN TECHNOLOGIES LIMITED (GB) | 2012-05-17 | — | — | US | claimed |
| EP-1519745-B1 | METHOD TO ENHANCE AN IMMUNE RESPONSE OF NUCLEIC ACID VACCINATION | LIPOXEN TECHNOLOGIES LTD (GB) | 2006-12-20 | — | — | EP | claimed |
| US-20050220858-A1 | Codelivery to a cell of nucleic acid and assistor protein (antigen) where the nucleic acid encodes an antigenic protein or which shares an epitope(s) with the assistor protein; the nucleic acid is entrapped in liposome intravesicular space; assistor protein is on the liposome surface; synergistic | OPKO PHARMACEUTICALS, LLC | 2005-10-06 | — | — | US | claimed |
| EP-1519745-A1 | METHOD TO ENHANCE AN IMMUNE RESPONSE OF NUCLEIC ACID VACCINATION | Lipoxen Technologies Limited (GB) | 2005-04-06 | — | — | EP | claimed |
| WO-2004004758-A1 | METHOD TO ENHANCE AN IMMUNE RESPONSE OF NUCLEIC ACID VACCINATION | LIPOXEN TECHNOLOGIES LIMITED (GB) | 2004-01-15 | — | — | WO | claimed |
| US-20240100183-A1 | COMPOSITIONS COMPRISING MOLECULES FOR CYSTIC FIBROSIS TREATMENT | NATIONAL INSTITUTES OF HEALTH | 2024-03-28 | — | — | US | disclosed |
| US-11904006-B2 | Poly(diaminosulfide) particle-based vaccine | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2024-02-20 | — | — | US | disclosed |
| US-20240050462-A1 | PHARMACEUTICAL COMPOSITION CONTAINING DOUBLE-STRANDED RIBONUCLEIC ACID INHIBITING EXPRESSION OF COMPLEMENT C5 | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2024-02-15 | — | — | US | disclosed |
| US-20230414787-A1 | GENE KNOCK-OUT FOR TREATMENT OF GLAUCOMA | UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2023-12-28 | — | — | US | disclosed |
| US-20230405148-A1 | GENE THERAPY FOR ALZHEIMER'S DISEASE | CORNELL UNIVERSITY | 2023-12-21 | — | — | US | disclosed |
| US-20230277483-A1 | COMPOSITIONS AND METHODS TO TREAT INFLAMMATION | NATIONAL INSTITUTES OF HEALTH | 2023-09-07 | — | — | US | disclosed |
| US-20020188023-A1 | Compound | IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE (GB) | 2002-12-12 | — | — | US | disclosed |
| EP-0966478-A4 | NOVEL HEDGEHOG-DERIVED POLYPEPTIDES | UNIV JOHNS HOPKINS MED (US) | 2002-08-21 | — | — | EP | disclosed |
| US-6214794-B1 | PROLIFERATION OR DIFFERENTIATION OF NONPOST MITOTIC NEURONAL CELLS WITH POLYPEPTIDES | THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE | 2001-04-10 | — | — | US | disclosed |
| US-6057091-A | DETECTION OF MODULATORS OF A CHOLESTEROL TRANSPORT PROTEIN; INCUBATE TRANSPOT PROTEIN AND MODULATOR AND COMPARE CHOLESTROL TRANSPORT IN IT PRESENCE AND ABSENCE | THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE | 2000-05-02 | — | — | US | disclosed |
| EP-0966478-A1 | NOVEL HEDGEHOG-DERIVED POLYPEPTIDES | THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 1999-12-29 | — | — | EP | disclosed |
| WO-1998030576-A1 | NOVEL HEDGEHOG-DERIVED POLYPEPTIDES | THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE (US) | 1998-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050220858-A1 | Codelivery to a cell of nucleic acid and assistor protein (antigen) where the nucleic acid encodes an antigenic protein or which shares an epitope(s) with the assistor protein; the nucleic acid is entrapped in liposome intravesicular space; assistor protein is on the liposome surface; synergistic | EXOSC5, EXOSC4, EXOSC10 | USP2 1016/4885CYP46A1 4578/4885LMNA 2363/4885 |
| US-20120121690-A1 | METHOD TO ENHANCE AN IMMUNE RESPONSE OF NUCLEIC ACID VACCINATION | EXOSC4, STING1, AEBP2 | USP2 833/4885CYP46A1 3740/4885LMNA 2441/4885 |
| US-20020188023-A1 | Compound | CYP46A1, CYP11B2, NR1H3 | USP2 2764/4885CYP46A1 1/4885LMNA 1627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.